Tislelizumab Approved for First-Line in ESCC

The Chinese immune checkpoint inhibitor has picked up its third indication within a year.
Medscape Medical News

source https://www.medscape.com/viewarticle/tislelizumab-receives-first-line-nod-unresectable-metastatic-2025a10005eq?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?